K-Ras, Intestinal Homeostasis and Colon Cancer

Author(s): Sanjay Goel, Jie Huang, Lidija Klampfer

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 10 , Issue 1 , 2015

Become EABM
Become Reviewer
Call for Editor


Activating Ras mutations, present in about 20% of human cancers, compromise the GTPase activity of Ras and therefore trigger accumulation of Ras in the GTP-bound state. Among the three family members, K-Ras, H-Ras and N-Ras, K-Ras is the most frequently mutated gene, with 30-50% of colon cancer patients harboring activating K-Ras mutations. Oncogenic mutations of K-Ras have been found at codons 12, 13, 61 and 146. Activation of Ras triggers constitutive activation of signaling pathways, including the MAPK and AKT pathways, which allows tumor cells to proliferate in the absence of growth factors and increases their survival. In addition, activated Ras triggers inflammation and thus promotes tumor progression in a cell non-autonomous manner. The presence of K-Ras mutations not only has prognostic value, but it also predicts the responsiveness of colon cancer patients to inhibitors of EGFR signaling.

Keywords: Colon cancer, EGFR inhibitors, inflammation, Ras.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 09 April, 2015
Page: [73 - 81]
Pages: 9
DOI: 10.2174/1574884708666131111204440

Article Metrics

PDF: 65
PRC: 2